KATO-III

The KATO-III cell line is a human gastric carcinoma model derived from the metastatic site of a poorly differentiated adenocarcinoma. These cells are widely utilized in research focused on gastric cancer, particularly for studying the molecular mechanisms driving tumor progression, drug resistance, and metastasis. The KATO-III cells exhibit an aneuploid karyotype, characterized by multiple chromosomal abnormalities, which contributes to their aggressive cancer phenotype. They are notably p53 deficient, a feature often associated with increased tumorigenicity and altered responses to chemotherapy, making them a valuable tool for investigating the role of p53 in gastric cancer.

KATO-III cells grow in suspension and display a rounded morphology. They possess a high capacity for proliferation, making them suitable for various in vitro applications, including drug screening and cytotoxicity assays. These cells are also used in studies of cell signaling pathways, as their aberrant signaling is a hallmark of gastric cancer pathogenesis. Researchers often utilize KATO-III cells to explore the efficacy of novel therapeutic agents, particularly those targeting HER2, EGFR, and other relevant oncogenic pathways. This cell line is essential for advancing our understanding of gastric cancer biology and for developing targeted therapies aimed at improving patient outcomes.

37°C, 5% CO₂, humidified atmosphere.

1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

At Cytion, we stand behind the quality and viability of our products. We guarantee that our cells will be viable at the start of culture for 60 days after shipment from our facilities. We assure that all materials conform to the specifications described in the Certificate of Analysis and/or Product Sheet.

For full details, please refer to our Warranty Statement.